Current Report Filing (8-k)
September 13 2022 - 9:17AM
Edgar (US Regulatory)
0001094038
false
0001094038
2022-09-13
2022-09-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
September 13, 2022
Date of Report (Date of earliest event reported)
MARKER THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
001-37939 |
45-4497941 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
3200 Southwest Freeway
Suite 2500
Houston, Texas |
|
77027 |
| (Address of principal executive offices) |
|
(Zip Code) |
(713) 400-6400
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
MRKR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 7.01 | Regulation FD Disclosure. |
On September 13, 2022, Marker Therapeutics, Inc.
(the “Company”) issued a press release to announce that the U.S. Food and Drug Administration (the “FDA”)
has awarded the Company a $2.0 million grant from the FDA’s Orphan Products Grant program to support the Company’s Phase 2
clinical trial of MT-401 for the treatment of post-transplant AML. A copy of the press release is furnished herewith as Exhibit 99.1 to
this Current Report on Form 8-K.
The information in this Item 7.01 of this Current
Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Marker Therapeutics, Inc. |
| |
|
|
| Dated: September 13, 2022 |
By: |
/s/ Peter Hoang |
| |
|
Peter Hoang |
| |
|
President and Chief Executive Officer |
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Nov 2023 to Nov 2024
